Treatment of murine cryptococcosis with liposome-associated amphotericin b

John R. Graybill, Philip C. Craven, Robert L. Taylor, Dwight M. Williams, Wayne E. Magee

Research output: Contribution to journalArticlepeer-review

150 Scopus citations


Liposomes were prepared to incorporate large amounts of amphotericin B. BALB/c mice were challenged with Cryptococcus neoformans and given liposome-associated amphotericin B (AMBL) or amphotericin B-deoxycholate (AMBD) intravenously. Mice that were treated with AMBL survived longer and had lower tissue counts of cryptococci than mice treated with AMBD or untreated control mice. The reduced acute toxicity of AMBL permitted much larger doses of amphotericin B to be given than were possible with AMBD. AMBL is a novel vehicle of administration that reduces toxicity and concentrates the drug in the appropriate target organs.

Original languageEnglish (US)
Pages (from-to)748-752
Number of pages5
JournalJournal of Infectious Diseases
Issue number5
StatePublished - May 1982

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Treatment of murine cryptococcosis with liposome-associated amphotericin b'. Together they form a unique fingerprint.

Cite this